# A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.

> **NCT06481150** · PHASE4 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 18 (actual)

## Conditions studied

- Hyperoxaluria

## Interventions

- **DRUG:** Tenapanor
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06481150
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-01
- **Primary completion:** 2025-09-14
- **Final completion:** 2025-09-14
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06481150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06481150, "A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06481150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*